All News

Bispecific antibodies have demonstrated adaptability and versatility when combined with immunotherapy and chemotherapy agents.

Planned interim results from the phase 3 DESTINY-Breast05 trial showed no new safety signals with T-DXd in the trial population.

The addition of certepetide to a FOLFIRINOX-based regimen was safe in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma.

A machine learning method for scoring tumor-infiltrating lymphocytes may address variability in pathologist measurements.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

An 80% disease metastasis–free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.

Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.

Artificial intelligence can be used to automate genetic counseling processes and streamline a patient’s communication with relatives regarding genetic risk.

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.

Gary Steinberg, MD, discusses the role of patient counseling and surveillance when using the gemcitabine intravesical system for BCG-unresponsive NMIBC.

An indirect comparison supports continuous therapy with zanubrutinib as a valuable treatment option in treatment-naïve CLL or SLL.

CRS, neurotoxicities, and infections are the most common AEs associated with BCMA- and GPRC5D-directed therapies in patients with multiple myeloma.

Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Physicians are no longer required to have special certification to administer vandetanib to patients with medullary thyroid cancer.

Experts at City of Hope explore innovative immunotherapy strategies for non-small cell lung cancer, highlighting efficacy and toxicity management in treatment.

A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.

Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.

Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.

Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.

Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Atebimetinib with gemcitabine and nab-paclitaxel achieved 9-month OS and PFS of 86% and 53%, respectively, in patients with pancreatic cancer in frontline settings.

The frontline treatment algorithm in SCLC is poised to look “radically different” in the upcoming years, according to Anne Chiang, MD, PhD.

In an interim safety analysis, no dose-limiting toxicities, unexpected AEs, or grade 3/4 AEs were reported in 10 patients treated for metastatic CRPC.

Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.

In patients with ES-ECLC treated with chemotherapy and immunotherapy, stereotactic body radiation therapy did not significantly improve overall survival.

Results from the phase 3 DESTINY-Breast09 trial will support the FDA’s decision on whether to approve T-DXd plus pertuzumab in frontline metastatic breast cancer.

CAR T-cell therapies or other agents that affect the immune system in the long term may be important to keep in mind for the management of SCLC.

Marc S. Raab, MD, PhD, details how agents such as carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.